Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

Orphan Drugs for CNS Diseases: R&DOrphan Drugs for CNS Diseases: R&D and Market 2014-2024 PR Newswire LONDON, January 16, 2014 Uncommon nerve disorders - new study explains technological and commercial prospects What's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts. So see what's possible for treating unusual neurological conditions. Avoid missing out. You gain data and financial analysis for that industry and market, appraising its outlooks. Find technological progress and commercial prospects, seeing potential gains. Read on to explore those treatments and find what their future could be worth. Forecasts and other analyses for therapy of rare (orphan) neurodegenerative disorders Our new study reveals sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials. Besides forecasting revenues to 2024, that work shows historical results, growth rates, and market shares. There you get a feel for technologies, regulatory outlooks, and developments (R&D). You also get 41 tables, 40 charts, and two interviews from the industry.